The latest news, views and analysis from the pharmaceutical industry’s frontline in the war on cancer. Updates on pharmaceutical and biotech oncology pipelines, regulatory decisions and market access news, and how healthcare systems needs to change to tackle one of the world’s biggest killers.
Bayer and the University of Texas MD Anderson Cancer Center have signed a five-year collaboration agreement to accelerate the development of novel targeted treatments for cancer.
Decision wipes $24 billion from share price
Up and coming immunotherapy company Autolus has published details of an ‘off switch’ safety features in its next generation CAR-Ts.
Adaptimmune has more good news from its SPEAR T-cell therapy, yesterday unveiling encouraging early results in four patients with myxoid/round cell liposarcoma (MRCLS).
One of the world’s foremost scientist and pioneer of genomics, Professor Sir John Sulston has died at the age of 75.
Ontruzant, the first biosimilar version of Roche’s Herceptin (trastuzumab) in Europe has been launched in the UK by MSD.
Owlstone Medical, the innovative company which promises to revolutionise the diagnosis of cancer by simply analysing a patient’s breath has been given a major funding boost.
Lantern Pharma, a pharma company which uses artificial intelligence to develop shelved oncology drugs has joined Genomics England’s groundbreaking industry partnership.
Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients.
The Pharma Challenge saw Amgen, Merck, IQVIA and uMotif collaborate with the NHS on a range of projects to improve care for cancer patients.